1. Search Result
Search Result
Results for "

Acetohexamide

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

10

Peptides

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0881
    Acetohexamide
    1 Publications Verification

    Potassium Channel Metabolic Disease Cancer
    Acetohexamide is an orally active first-generation sulfonylurea agent used in research related to type 2 diabetes and cancer. Acetohexamide exerts reductase activity in human erythrocytes. Acetohexamide stimulates the pancreas to secrete insulin. Acetohexamide inhibits ATP-sensitive potassium channels in the β cells of the pancreas. Acetohexamide can inhibit the formation of circular chemorepellent induced defects (CCIDs) in lymphendothelial cell (LEC) monolayers. Acetohexamide inhibits markers of epithelial-to-mesenchymal-transition and migration. Acetohexamide suppresses the synthesis of 12(S)-HETE. Acetohexamide can potentiate hypoglycaemic action .
    Acetohexamide
  • HY-B1103

    (±)-Hydroxyhexamid

    Drug Metabolite Cardiovascular Disease
    Hydroxyhexamide is a pharmacologically active metabolite of Acetohexamide, used as a hypoglycemic agents.
    Hydroxyhexamide
  • HY-P4154

    ALM-488

    Fluorescent Dye Neurological Disease Cancer
    Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
    Bevonescein
  • HY-P1103
    CTCE-9908
    1 Publications Verification

    CXCR Cancer
    CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908
  • HY-P2231A
    Cotadutide acetate
    1 Publications Verification

    MEDI0382 acetate

    GCGR Metabolic Disease
    Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
    Cotadutide acetate
  • HY-P10026

    LY-3457263

    Neuropeptide Y Receptor Metabolic Disease
    Nisotirotide (LY-3457263) is a subcutaneous injectable NPY2 receptor agonist. By mimicking peptide YY (PYY), Nisotirotide inhibits appetite and can be used in the research of diseases such as obesity and diabetes .
    Nisotirostide
  • HY-B0881R

    Reference Standards Potassium Channel Metabolic Disease Cancer
    Acetohexamide (Standard) is the analytical standard of Acetohexamide. This product is intended for research and analytical applications. Acetohexamide is an orally active first-generation sulfonylurea agent used in research related to type 2 diabetes and cancer. Acetohexamide exerts reductase activity in human erythrocytes. Acetohexamide stimulates the pancreas to secrete insulin. Acetohexamide inhibits ATP-sensitive potassium channels in the β cells of the pancreas. Acetohexamide can inhibit the formation of circular chemorepellent induced defects (CCIDs) in lymphendothelial cell (LEC) monolayers. Acetohexamide inhibits markers of epithelial-to-mesenchymal-transition and migration. Acetohexamide suppresses the synthesis of 12(S)-HETE. Acetohexamide can potentiate hypoglycaemic action .
    Acetohexamide (Standard)
  • HY-W703629

    Isotope-Labeled Compounds Potassium Channel Metabolic Disease
    Acetohexamide-d11 is the deuterium labeled Acetohexamide (HY-B0881). Acetohexamide is a first-generation sulfonylurea agent used in research related to type 2 diabetes; it stimulates the pancreas to secrete insulin.Acetohexamide inhibits ATP-sensitive potassium channels in the β cells of the pancreas .
    Acetohexamide-d11
  • HY-B1103R

    (±)-Hydroxyhexamid (Standard)

    Reference Standards Drug Metabolite Cardiovascular Disease
    Hydroxyhexamide (Standard) is an analytical standard for Hydroxyhexamide. This product is intended for research and analytical applications. Hydroxyhexamide is a pharmacologically active metabolite of Acetohexamide, used as a hypoglycemic agents.
    Hydroxyhexamide (Standard)
  • HY-P1103A

    CXCR Cancer
    CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908 TFA
  • HY-P4757

    Parasite Others
    N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
    N1-Glutathionyl-spermidine disulfide
  • HY-P2231
    Cotadutide
    1 Publications Verification

    MEDI0382

    GCGR Metabolic Disease
    Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
    Cotadutide
  • HY-P1321

    1229U91; GW1229

    Neuropeptide Y Receptor Neurological Disease
    GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
    GR231118
  • HY-P1321A

    1229U91 TFA; GW1229 TFA

    Neuropeptide Y Receptor Neurological Disease
    GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
    GR231118 TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: